BBIO Overview
Upcoming Projects (BBIO)
-
Evaluating BridgeBio's (BBIO) Phase 3 ATTRibute-CM Trial Results for Attruby (Acoramidis) in ATTR-CM Patients
Ticker: BBIO
Execute By: Jan 31, 2025
Executed Projects (BBIO)
-
Examining BridgeBio's Infigratinib PROPEL 2 Trial Results in Achondroplasia and Beyond
Ticker: BBIO
Executed On: Jun 27, 2024 at 12:00 PM EDT -
Examining the results of the Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM by BridgeBio Pharma presented at International Symposium of Amyloidosis (ISA)
Ticker: BBIO
Executed On: Jun 25, 2024 at 12:00 PM EDT -
Reviewing the additional data from BridgeBio phase 3 attribute-cm study showing acoramidis increases serum transthyretin in transthyretin amyloid cardiomyopathy (ATTR-CM)
Ticker: BBIO
Executed On: Jun 20, 2024 at 02:00 PM EDT -
Reviewing the long-Term Data from BridgeBio's Phase 2 Study of Glycosylated Alpha-dystroglycan (⍺DG) levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Ticker: BBIO
Executed On: Dec 15, 2023 at 12:30 PM EST -
Examining the Phase 1 data of Intellia's NTLA-2001 and outcomes data from the phase 3 attribute-cm trial of BridgeBio's acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Tickers: NTLA, BBIO
Executed On: Nov 22, 2023 at 09:00 AM EST -
An updated look at the results from the ATTRibute-CM trial of Acoramidis in patients with transthyretin amyloid cardiomyopathy
Tickers: BBIO, PFE, ALNY
Executed On: Sep 06, 2023 at 10:30 AM EDT -
Discussing the ATTRibute Part B results on Acoramidis for patients with ATTR cardiomyopathy.
Tickers: BBIO, PFE, ALNY
Executed On: Jul 20, 2023 at 09:00 AM EDT -
A Third View: Discussing acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Tickers: BBIO, PFE, ALNY
Executed On: Jul 12, 2023 at 01:00 PM EDT -
A Second View: A discussion of acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Tickers: BBIO, PFE, ALNY
Executed On: Jul 11, 2023 at 01:30 PM EDT -
A discussion of acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy).
Tickers: BBIO, PFE, ALNY
Executed On: Jul 07, 2023 at 01:00 PM EDT -
Digging into the recent Phase 2 Cohort 5 results of Bridgebio's ifigratinib in achondroplasia
Tickers: BBIO, BMRN, ASND
Executed On: Mar 17, 2023 at 11:00 AM EDT -
A Second View: Examining the achondroplasia treatment landscape with a focus on BBIO's infigratinib, BMRN's Voxzogo (vosoritide) & ASND's TransCon CNP
Tickers: BBIO, BMRN, ASND
Executed On: Jan 31, 2023 at 12:00 PM EST -
Examining the achondroplasia treatment landscape with a focus on BBIO's infigratinib, BMRN's Voxzogo (vosoritide) & ASND's TransCon CNP
Tickers: BBIO, BMRN, ASND
Executed On: Jan 12, 2023 at 12:00 PM EST -
A discussion of EB-101 from Abeona Therapeutics as a potential autologous cell therapy in recessive dystrophic epidermolysis bullosa (RDEB)
Tickers: ABEO, KRYS, BBIO
Executed On: Oct 26, 2022 at 08:30 PM EDT -
A Second View: Discussing the recent phase 2 results from infigratinib in children with achondroplasia and how it may compare to Biomarin's Voxzogo (vosoritide)
Tickers: BBIO, BMRN
Executed On: Aug 03, 2022 at 02:00 PM EDT -
Discussing the recent phase 2 results from infigratinib in children with achondroplasia and how it may compare to Biomarin's Voxzogo (vosoritide)
Tickers: BBIO, BMRN
Executed On: Aug 02, 2022 at 12:00 PM EDT -
A Second Look: Discussing the potential of acoramidis following the failure on Part A of the ATTRibute-CM study
Tickers: BBIO, PFE
Executed On: Jan 24, 2022 at 12:00 PM EST -
A look at potential of acoramidis following the failure on Part A of the ATTRibute-CM study
Tickers: BBIO, PFE
Executed On: Jan 18, 2022 at 01:00 PM EST
Expired Projects (BBIO)
-
Discussing BridgeBio’s infigratinib (BBP-831) in Cholangiocarcinoma
Ticker: BBIO
Execute By: Jun 30, 2021
Upcoming & Overdue Catalysts (BBIO)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BBIO)
-
Bridgebio's (BBIO) Infigratinib (BBP-831) in Cholangiocarcinoma PDUFA date Estimated for June 1, 2021, based on 6-month timeline
Ticker: BBIO
Occurred on: May 28, 2021
Strategic Initiatives (BBIO)
-
BridgeBio Pharma (BBIO) Terminates Merger Process With Its Subsidiary Eidos Therapeutics (EIDX)
Tickers: BBIO, EIDX
Announcement Date: Oct 14, 2019 -
Alexion (ALXN) And Eidos' (EIDX) subsidiary - BridgeBio (BBIO) Agree On Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine License
Tickers: ALXN, EIDX, BBIO
Announcement Date: Sep 09, 2019
